Parallel Health World News Logo

Parallel Health World

cropper
  • Home
  • Categories
    • EcoHealth Trends
    • Healing Naturally
    • Age-Defying Diets
    • Supplement Savvy
    • Mind-Body Synergy
    • Finance and Health
    • Biolimitless
    • Tech Hacks
    • Health & Medicine
    • Political
    • BioBuzz
    • Holistic Rehabilitation Techniques
    • Practitioner Insights
    • AI In Healthcare
  • Featured Business Profiles
December 31.2025
1 Minute Read

Discover the Hidden Power of Rare Disease Research Today

Did you know fewer than 5% of rare diseases have approved treatments, even though over 300 million people live with a rare disease worldwide? These statistics reveal an urgent, often overlooked health crisis—but they also highlight a powerful opportunity for innovation and hope

Unveiling the Impact: Startling Facts About Rare Disease Research

  • Rare diseases affect over 300 million people worldwide.
  • Less than 5% of rare diseases have approved treatments.
"For every rare disease patient, innovative research is hope." – Leading Clinical Research Expert

Diverse group at rare disease awareness event supporting rare disease research

What You'll Learn About Rare Disease Research

  • Why rare disease research is critical to medical advancement
  • The landscape of rare diseases and the global research network
  • How clinical trials and patient advocacy transform lives
  • Ways to get involved and make a difference

Why Rare Disease Research Matters: Advancements, Hope, and the Future

Rare Diseases: The Unseen Health Crisis

  • Definition and prevalence of rare diseases
  • Challenges faced by rare disease patients and families

Rare disease research shines a spotlight on health conditions impacting fewer than 200,000 people per disease in the United States alone. These rare diseases—ranging from genetic disorders to resistant KD and beyond—collectively touch the lives of over 300 million people worldwide. Despite their prevalence, families living with rare diseases often feel isolated due to a lack of information, limited support, and few available treatments. The disease community constantly depends on the few clinical care specialists and information specialists available, yet many conditions—such as progeria or Batten disease—have no current cures. Rare disease patients face lengthy diagnostic journeys, high medical costs, and uncertainty, making research vital not only for finding therapies but also for hope itself.

The challenges for rare disease patients and their families are immense. Treatment options for most rare diseases are scarce, with less than 5% of these diseases currently having an FDA-approved therapy. The absence of adequate clinical trials and specialized infusion center support only adds to the burden for patients and clinical research teams alike. This gap is why patient advocacy and a robust research network are so crucial, as they work tirelessly to raise awareness and develop new solutions, ensuring that the voices of people living with rare disease are finally heard.

Family supporting a young woman affected by a rare disease; rare disease patient community and family support

Building a Rare Disease Research Network: Collaboration for Breakthroughs

The Role of Clinical Research and Clinical Trials

  • How clinical trials advance new treatments for rare diseases
  • Leading institutions, like the California Center, championing research

Clinical research and clinical trials are the engines that power innovation in rare disease research. Through rigorous studies, clinical research experts explore new drugs, gene therapies, and novel approaches, bringing hope to people living with rare disease. Every clinical trial is a critical step forward, offering rare disease patients opportunities to participate and shape the future of medical care. Institutions such as the California Center stand at the forefront, not only leading clinical trials but also serving as information specialists for disease patients and their families. Their commitment bridges the gap between scientific discovery and patient support, fostering international collaboration and sharing summaries of recent breakthroughs.

Networking is central to rare disease research progress. A research network spanning continents allows clinicians, scientists, and patient advocacy groups to pool data, share best practices, and optimize the development of targeted therapies. Expert clinicians and information specialists work together to respond to your inquiry, ensuring that patients from all backgrounds—whether seeking clinical trials or daily clinical care—receive guidance, support, and the latest clinical trial opportunities. By connecting rare disease communities globally, these networks accelerate the translation of research findings into real-world changes, ultimately improving quality of life for millions.

Effective communication is also essential for research teams and advocacy groups to share updates and coordinate efforts. Leveraging innovative tools such as video email platforms can help streamline outreach, making it easier to connect with patients, clinicians, and supporters across the globe.

Clinical research team advancing rare disease research and discussing data in a high-tech laboratory

Patient Advocacy: Giving Rare Disease Patients a Voice

  • The importance of empowering rare disease patient communities
"Patient advocacy accelerates rare disease research outcomes." – Patient Advocate

Patient advocacy is one of the most influential forces in the field of rare disease research. Dedicated advocacy groups ensure that rare disease patients are not just subjects of research but active participants shaping priorities and policies. By raising awareness, sharing stories, and mobilizing resources, patient advocacy creates a unified voice for the rare disease patient community—connecting families with expert clinicians, clinical research teams, and opportunities to participate in pivotal clinical trials. These efforts pave the way for additional support services, such as information specialists and outreach through disease community organizations, making information about clinical trials and new treatments more accessible than ever.

Advocacy also drives legislative change and helps secure funding for rare disease research initiatives. Organizations work tirelessly to promote events like Disease Day, encourage donations, and enlist volunteers to support their cause. By empowering people living with rare disease, advocacy networks ensure patient priorities remain at the heart of research, turning hope into action—and research outcomes into meaningful change.

How to Support Rare Disease Research: Getting Involved

  • Join awareness events on Disease Day
  • Participate in clinical research or clinical trials
  • Donate to research networks or patient advocacy groups
  • Share rare disease stories to raise visibility

You can play a key role in advancing rare disease research, no matter your background. Participation starts with raising awareness—attend events like Disease Day, where the rare disease community comes together to spotlight urgent needs and celebrate progress. Learn how to enroll in clinical trials or support research initiatives at leading centers such as the California Center. Clinical trials often provide opportunities for both patients and healthy volunteers, paving the way for medical breakthroughs that benefit the entire disease community.

Financial support is another lifeline for research networks and patient advocacy groups. Even small donations empower organizations to fund studies, train clinical research specialists, and offer information services to people living with rare disease. By sharing rare disease stories online, through social media, or within your community, you help raise the visibility of these urgent health issues and encourage others to get involved. Every action you take brings hope closer to millions around the world searching for answers and cures.

Volunteers supporting rare disease research at Disease Day; raising awareness and collecting donations

People Also Ask About Rare Disease Research

What is rare disease research?

  • Rare disease research seeks to understand and develop treatments for diseases affecting fewer than 200,000 people, driving innovation in medicine.

Rare disease research is a specialized field focused on uncovering the underlying causes, developing diagnostics, and creating therapies for rare diseases that impact smaller but significant segments of the global population. By advancing clinical research and supporting robust research networks, scientists and clinicians strive to address the gaps that traditional medical research leaves behind. These efforts not only help rare disease patients but often lead to discoveries benefiting a broader array of health conditions. Participating in a clinical trial or engaging with patient advocacy can fuel this essential work.

Can I get paid for having a rare disease?

  • Some clinical trials and research studies offer compensation to rare disease patients for participation, depending on the study and location.

Yes, compensation is sometimes available for individuals participating in clinical trials and clinical research focused on rare diseases. The amount and availability of compensation can vary widely, depending on the organization, the particular trial, and local regulations. Clinical trials conducted at institutions like the California Center often provide stipends or cover travel expenses for rare disease patient volunteers. If you are interested in participating, consult clinical care providers or research network resources for opportunities to participate and guidance.

What is the rarest disease in the world?

  • Conditions like ribose-5-phosphate isomerase deficiency are among the rarest, with only a handful of documented cases globally.

Ribose-5-phosphate isomerase deficiency is considered one of the rarest diseases, with only a few cases recorded worldwide. Research into such ultra-rare diseases is particularly challenging due to the scarcity of patients, limited clinical data, and obstacles in designing clinical trials. Nonetheless, these cases underscore the urgent need for international research networks and disease day awareness campaigns—ensuring every rare disease patient, no matter how small the community, receives attention and hope for a better future.

What rare disease has no cure?

  • Many rare diseases, such as progeria or Batten disease, currently have no cures, underscoring the need for more clinical research.

Despite advances in medicine, many rare diseases remain without any approved cures. Progeria, Batten disease, and hundreds of other rare diseases still challenge researchers, making it critical to fund clinical trials and build thriving research networks. Patient advocacy plays an indispensable role by highlighting these needs, connecting families with information specialists, and driving support for ongoing research. Involvement in disease day events, clinical trial participation, or donations can ignite the progress needed to find new treatments.

FAQs About Rare Disease Research

  • What is the definition of a rare disease?

A rare disease in the United States is defined as a condition affecting fewer than 200,000 people at any given time. These diseases can be genetic, acquired, or even resistant KD (Kawasaki disease). Each rare disease is distinct, requiring targeted clinical research for diagnosis and treatment.

  • How can individuals participate in rare disease clinical trials?

Individuals interested in clinical trial participation can start by consulting with clinical care providers, contacting information specialists at leading centers, or registering with clinical research networks. Many organizations offer opportunities to participate through online platforms, disease day events, and local advocacy groups.

  • Which organizations fund rare disease research initiatives?

Multiple organizations support rare disease research, including government agencies like the National Institutes of Health (NIH), disease-specific advocacy foundations, the California Center, pharmaceutical companies, and global research networks. These funders underpin the scientific progress that fuels hope for millions of rare disease patients.

Keynote speaker presenting breakthroughs in rare disease research at a global conference

Key Takeaways: The Vital Role of Rare Disease Research

  • Rare disease research fuels medical breakthroughs for all.
  • Patient advocacy and research networks are essential for progress.
  • Your involvement can lead to hope and change for millions.

Explore the Rare Disease Research Network Today

  • Ready to power progress? Join our rare disease research campaign and make an impact—download our exclusive resource or sign up for updates now.

Inspiring global research network—scientists and advocates collaborating across the world

Comparison of Rare Disease Research Initiatives: Focus Areas, Funders, and Participation Opportunities

Initiative / Network Key Focus Areas Main Funders Participation Opportunities
California Center for Rare Diseases Genetic Rare Diseases, Clinical Trials, Patient Advocacy NIH, Private Foundations Patient enrollment, Disease Day events, Research collaborations
Global Rare Disease Research Network International Collaboration, Data Sharing, New Drug Development Government Grants, Industry Partners Clinical trial participation, Virtual seminars, Advocacy volunteer work
Rare Disease Patient Advocacy Foundation Awareness, Community Education, Research Funding Donor Support, Corporate Sponsorships Donations, Story sharing, Peer mentoring programs
NIH Office of Rare Diseases Policy, Funding, Research Coordination Federal Government Research proposals, Training, Public consultations

Conclusion

Your voice and actions make a difference—explore rare disease research, join a clinical trial, share a story, or donate today to help pave the path to hope for millions.

As you continue your journey in supporting rare disease research, consider how innovative communication tools can amplify your impact—whether you're sharing patient stories, organizing virtual events, or connecting with global advocates. Harnessing the power of video email technology can help you reach wider audiences and foster stronger collaborations within the rare disease community. By embracing new ways to engage and inform, you not only raise awareness but also inspire action and drive meaningful change. Explore how digital solutions can elevate your advocacy and help bring hope to those who need it most.

Sources

  • NIH Genetic and Rare Diseases Information Center – https://rarediseases.info.nih.gov
  • Rare Disease Day – https://www.rarediseaseday.org
  • EURORDIS – https://www.eurordis.org
  • Global Genes – https://globalgenes.org
  • ClinicalTrials.gov – https://clinicaltrials.gov

Rare disease research is a critical field that addresses the needs of over 30 million Americans affected by various rare conditions. The National Institutes of Health (NIH) emphasizes the importance of this research, noting that while individual rare diseases are uncommon, collectively they have a significant public health impact. (nih.gov)

The National Organization for Rare Disorders (NORD) is a nonprofit organization dedicated to supporting individuals with rare diseases through advocacy, research funding, education, and networking among service providers. (rarediseases.org)

Additionally, the Rare Diseases Clinical Research Network (RDCRN), funded by the NIH, facilitates collaboration among scientists, clinicians, and patient advocacy groups to study over 280 rare diseases. This network aims to advance medical research by supporting clinical studies and promoting data sharing. (ncats.nih.gov)

For those seeking to participate in clinical trials or connect with research initiatives, Know Rare offers resources to help navigate the complexities of rare disease research. Their platform provides access to support, tools, and knowledge from top leaders and researchers in the field. (knowrare.com)

Engaging with these organizations can provide valuable insights and opportunities to contribute to the advancement of rare disease research.

Health & Medicine

23 Views

0 Comments

Write A Comment

*
*
Please complete the captcha to submit your comment.
Related Posts All Posts
10.11.2026

What the EU's Piracy Watch List Means for VPNs and yt-dlp Users

Update Understanding the EU Piracy Watch List SubmissionsThe recent EU Piracy Watch List submissions have raised eyebrows across the tech and entertainment sectors. Among those targeted are the open-source video downloader yt-dlp and several prominent VPN providers including NordVPN and ExpressVPN. This consultation, which began on June 11 and concluded on September 21, has opened a dialogue about the intersection of technology and intellectual property rights.The Implications of the Watch ListThe European Commission has clarified that the Watch List is a reputational tool, not an enforcement measure. It categorizes services that rights holders consider problematic without asserting any legal violations. This approach seeks to encourage improvements in the copyright landscape while fostering open dialogue between rights holders and technology companies. For users, understanding this distinction is crucial as it may impact how these tools are utilized in the future.Community Reaction and Historical ContextThe inclusion of yt-dlp—a tool that allows users to download online media—illustrates a growing tension between copyright enforcement and technological accessibility. Historically, attempts to label similar technologies as criminal have often backfired, leading to increased popularity and community advocacy for such projects. As the music and film industries navigate these complexities, reactions from users and developers alike indicate that the digital community remains skeptical of broad copyright enforcement measures.What’s Next for VPN and Downloading Technologies?With the Watch List slated for updates in 2027, stakeholders from both the entertainment and technology sectors are closely monitoring the developments. The role of VPN providers, often seen as essential privacy measures, may face scrutiny, challenging their users' anonymity and freedom online. As suggestions for inclusion continue to evolve, the reliance on lawful technologies underscores the importance of balancing intellectual property protection with user rights and privacy.Empowering Yourself with KnowledgeAs this situation unfolds, it's vital for professionals, consumers, and advocates to stay informed. Understanding how tools like yt-dlp and VPNs can be both helpful and contentious is key to navigating the evolving digital landscape. This knowledge empowers users to make informed choices about their online presence and engagement with media.

10.10.2026

Unlock Strong Arms: The Power of Dumbbell Hammer Curls Explained!

Update The Essential Guide to Dumbbell Hammer CurlsThe dumbbell hammer curl is a popular exercise amongst fitness enthusiasts aiming to strengthen their biceps and brachialis, the muscle lying beneath the biceps brachii that contributes to upper arm size. When performing the hammer curl, you hold a dumbbell in each hand with your palms facing each other, emphasizing the right form is crucial for effective and safe execution.Mastering the TechniqueStand upright with a dumbbell held in each hand, arms hanging by your sides. As you curl one dumbbell towards your shoulder, make sure to keep your thumb pointed vertically. It’s important to curl until the dumbbell reaches the highest point without moving the elbow forward; this promotes muscle engagement and minimizes injury risk. Remember to keep your torso stable, using your core to support your movement.Expert tips highlight the significance of using an appropriate weight, maintaining proper control during both the lifting and lowering phases, and performing 3 sets of 8-10 reps for optimal results. If you're alternating arms, ensure that you’re counting reps individually, promoting a balanced workout.Workout Integration StrategiesWhen crafting your workout routine, consider incorporating hammer curls as part of a pull day, mixed with other upper body exercises. They can be paired with chin-ups and rows to enhance your training program’s effectiveness. For a more focused approach, adding hammer curls early in your routine can stimulate growth in your biceps and contribute to overall arm development.Evaluating Effectiveness: Are Hammer Curls Necessary?While hammer curls effectively target the biceps and are especially useful for engaging the brachialis, their necessity can vary based on your fitness goals and existing workout structure. Many strength-training programs already activate the brachialis through other exercises such as close-grip lat pulldowns and seated cable rows. If you’re missing the brachialis in your routine, hammer curls might be an excellent addition to ensure balanced development.However, fitness experts express caution against relying solely on hammer curls. While they can be a safe and comfortable option for most individuals, variations in exercise can yield better overall strength outcomes. Engaging in diverse compound movements helps avoid plateaus and enhances muscular distribution across the arms.Integrating AlternativesFor those looking to diversify their workouts, consider alternatives such as incline dumbbell hammer curls that take advantage of an inclined bench position to further challenge muscle fibers. This variation alters the angle of resistance and can provoke new forms of muscle engagement, enhancing your overall strength development.In summary, dumbbell hammer curls can certainly play a role in a balanced arm strengthening regimen. Despite their limited necessity in programs already rich with brachialis-targeting exercises, they provide a solid exercise option for isolation and can combat potential strength imbalances when performed correctly.Final Insights: What’s Next?To maximize the benefits of hammer curls and achieve substantial growth in your arm strength, focus on proper technique and appropriate weight selection. Take the time to reflect on your personal fitness goals and consider how hammer curls and their variations can fit into your broader training plan for the best results.

10.06.2026

Discover the Heart of Mental Health Support at Park Center Nashville

Update A Deep Dive into Park Center Nashville's ImpactAs mental health continues to take center stage in discussions about community well-being, organizations like Park Center Nashville play a pivotal role in providing necessary services to those in need. In a recent episode of the NFM Podcast, hosts Abby Miranda and Collin Schoen engage with Adam Stainbrook and Stephen Formosa from the organization to unpack the depth and breadth of their mission.The Crucial Role of Community-Based SupportCommunity-based mental health support is more than just words; it’s a lifeline for many. Park Center Nashville embodies this by offering a range of services that focus on healing and resilience. Adam Stainbrook and Stephen Formosa elaborated on how holistic approaches to wellness can make a significant difference in the lives of Nashville residents. By fostering connections, they aim to not only treat mental health issues but also empower individuals to lead fulfilling lives.Celebration of Courage: More Than Just an EventThe upcoming “Celebration of Courage” event is a major highlight for the organization and the community. Scheduled to take place on [insert date], this event will be a significant gathering that showcases the strength and resilience of individuals overcoming mental health challenges. Stephen Formosa described how this celebration is designed to bring people together, raise awareness, and highlight the importance of mental health support. It’s a reminder that courage comes in many forms, and community support can amplify this strength.Get Involved: Joining the Movement for Mental HealthThe NFM Podcast serves as a platform to encourage community engagement, urging Nashville residents to take an active role in supporting mental health initiatives. Whether it's through volunteering, attending events, or simply sharing stories of resilience, everyone can contribute to a more supportive environment. Adam Stainbrook emphasized that the collective effort of the community can pave the way for a stronger, more connected Nashville.Why Mental Health Matters in Nashville and BeyondAs mental health awareness continues to evolve, the narrative shifts towards the importance of educated conversations that foster understanding and support. Events and organizations dedicated to mental health remind us that it is a community issue, not just an individual one. With leaders like those at Park Center Nashville, there is hope and encouragement for those affected by mental health struggles.For anyone interested in learning more about Park Center’s programs or getting involved, more information is available at parkcenternashville.org.

Where Conventional Meets Natural for a Healthier You

Parallel Health World News offers clarity and actionable knowledge for those eager to harmonize the best of both medical worlds, helping its audience achieve a truly integrative approach to health and wellness.

Advertise
Parallel Health World News
SeamanDan.com
Dan Seaman Media Press Pass

ABOUT US
SeamanDan LLC is a modern news media agency creating niche digital channels that inform and engage. We specialize in launching focused platforms that deliver impactful content.  Our current brands include:
Parallel Health World
AI Insights Hub
MLM News AI
Rider Safe News
Meme Crypto News
Rugged Trails Network
Recreation Wave
Outdoor Odyssey News
Eco-Innovation Hub
Metal Green Innovators
Autism Foundation News

At SeamanDan LLC, we don't just report the news we create platforms that build communities, foster trust, and drive forward-thinking conversations.  Can we build a channel for you?

© 2026 Parallel Health World News All Rights Reserved. 810 N Main St #187, Spearfish, SD 57783 . Contact Us . Terms of Service . Privacy Policy

{"company":"Parallel Health World News","address":", ,  ","city":"","state":"","zip":"","email":"seamandan@seamandan.com","tos":"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","privacy":"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"}

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*